-
公开(公告)号：US20210317228A1
公开(公告)日：2021-10-14
申请号：US16950522
申请日：2020-11-17
发明人： Bradley R. Pearse , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jonathan Philip Belk , Matthew Duncan Smith
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US20190144558A1
公开(公告)日：2019-05-16
申请号：US16168816
申请日：2018-10-23
发明人： Bradley R. Pearse , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jonathan Philip Belk , Matthew Duncan Smith
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US20210369854A1
公开(公告)日：2021-12-02
申请号：US17244721
申请日：2021-04-29
摘要： The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.
-
公开(公告)号：US10882915B2
公开(公告)日：2021-01-05
申请号：US16168816
申请日：2018-10-23
发明人： Bradley R. Pearse , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jonathan Philip Belk , Matthew Duncan Smith
IPC分类号： C07K16/28 , A61K35/545 , C07K7/64 , A61P37/06 , A61P35/00 , A61K47/68 , A61K38/00 , A61K35/12 , A61K39/00
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US20210206872A1
公开(公告)日：2021-07-08
申请号：US17103866
申请日：2020-11-24
发明人： Bradley R. Pearse , Michael Cooke , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jacob Glanville
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US20200276326A1
公开(公告)日：2020-09-03
申请号：US16851082
申请日：2020-04-16
摘要： The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and/or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.
-
公开(公告)号：US20190153114A1
公开(公告)日：2019-05-23
申请号：US16168823
申请日：2018-10-23
发明人： Bradley R. Pearse , Michael Cooke , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jacob Glanville
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US11572411B2
公开(公告)日：2023-02-07
申请号：US16950522
申请日：2020-11-17
发明人： Bradley R. Pearse , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jonathan Philip Belk , Matthew Duncan Smith
IPC分类号： C07K16/28 , A61K35/545 , C07K7/64 , A61P37/06 , A61P35/00 , A61K47/68 , A61K38/00 , A61K35/12 , A61K39/00
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
公开(公告)号：US20210371524A1
公开(公告)日：2021-12-02
申请号：US17244856
申请日：2021-04-29
发明人： Rahul Palchaudhuri , Bradley R. Pearse , Hillary Adams , Sean McDonough , Michael Cooke , Anthony Boitano
摘要： Disclosed are anti-CD45 antibodies and antibody drug conjugates (ADCs) useful in therapeutic methods, including targeting CD45 expressing hematopoietic stem cells (HSCs) or immune cells prior to transplantation.
-
公开(公告)号：US10899843B2
公开(公告)日：2021-01-26
申请号：US16168823
申请日：2018-10-23
发明人： Bradley R. Pearse , Michael Cooke , Anthony Boitano , Rahul Palchaudhuri , Sean McDonough , Rajiv Panwar , Jacob Glanville
IPC分类号： C07K16/28 , A61P35/00 , A61K35/545 , C07K7/64 , A61P37/06 , A61K47/68 , A61K38/00 , A61K35/12 , A61K39/00
摘要： The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.017 秒)
